---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-248289"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2026-05-29T20:10:56+00:00"
generated_at: "2026-05-29T20:12:08.351904+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma appoints David Friedman to board; Megan Boston resigns as director but remains CFO

## Summary
- David Friedman joined board as Class III director effective May 22, 2026; term until 2028 annual meeting.
- Friedman granted options to purchase 35,000 shares at closing price on May 26, 2026; vesting by next annual meeting or 1 year.
- Megan Boston resigned from board effective May 22, 2026; continues as CFO and secretary; no dispute.
- Friedman entitled to standard non-employee director compensation; will enter indemnification agreement.

## SEC filing metadata
- accession: 0001193125-26-248289
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2026-05-29T20:10:56+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/0001193125-26-248289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/bntc-20260522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-248289
- JSON: https://secwatch.observer/filing/0001193125-26-248289.json
- Plain text: https://secwatch.observer/filing/0001193125-26-248289.txt

## Source-grounded claims
- claim_id: 46992999b3
  claim: Megan Boston resigned as Director at Benitec Biopharma Inc..
  evidence_excerpt: On May 22, 2026, Megan Boston, the Company’s chief financial officer and secretary and a member of the Board since 2016, notified the Board of her decision to resign solely from the Board and rotated off the Board as part of the Company’s ongoing Board composition and governance review.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/0001193125-26-248289-index.htm
- claim_id: d65cc0a1f2
  claim: David Friedman was appointed as Director at Benitec Biopharma Inc..
  evidence_excerpt: On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/0001193125-26-248289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.